While the prices of four categories of medical devices - coronary stents, drug-eluting stents, condoms, and intrauterine devices - are already fixed by NPPA, the prices of the rest are fixed by the manufacturers themselves

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical

Bombay High Court has directed the Indian drug regulator National Pharmaceutical Pricing Authority (NPPA) to examine if it can cap per-year increase in N-95 masks at 10 per cent as per rules related to essential drugs

A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug

N-95 masks were earlier being sold in the market for Rs 150 to 300 per unit, but prices have been reduced after the advisory by the NPPA

Share Market Update : Domestic indices gained on Thursday on back of bullish global equities after remarks by US President suggested that US and Iran were refraining from further military action.

Most in the Indian pharma industry are hopeful that the new National List of Essential Medicines (NLEM) expected in 2020 will not be too disruptive

Share Market : Key benchmark indices Sensex and Nifty turned volatile and ended lower on Monday, tracking global equities

Domestic cancer drug sales are growing at 20 per cent annually for the past few years, while global growth is half of that

The pharma industry is today growing at around 11 per cent per annum as compared to a high of around 15 per cent about five years ago.

In March, the rates were brought down for around 380 drugs, with some cuts going to as much as 80-90 per cent under trade margin rationalisation.

The lawsuit accuses Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other companies to inflate drug prices, by more than 1,000% in some cases

In as many as 666 cases, pharma companies are yet to disgorge excess profits accrued by overcharging customers under the Drug Prices Control Orders. The DoP has now made a one-time settlement offer on their total outstanding dues, provided they collectively cough up Rs 3,501 crore and drop their lawsuits

In early March, the National Pharmaceutical Pricing Authority (NPPA), India's drug price regulator, fixed the ceiling prices of 463 brands of cancer medicines.